Which hedge funds own BCRX? BIOCRYST PHARMACEUTICALS INC, Q2 2026 13F holders
54 tracked hedge funds disclosed a position in BCRX (BIOCRYST PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $918.5m in total. The largest holder by portfolio weight is Vestal Point Capital, LP at 1.9% of its book. 13 opened a new position this quarter: Moore Capital Management, LP, PFM Health Sciences, LP, Aquatic Capital Management LLC, Gsa Capital Partners LLP. 11 exited: Capricorn Fund Managers Ltd, Hillsdale Investment Management Inc., Dark Forest Capital Management LP.
- 54
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 13
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 11
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $23.1m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $13.3m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $918m
- Combined value Sum of the holders' reported positions in the security.
- 4.4%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Capricorn Fund Managers Ltd | 0.3% | $1.9m |
| Hillsdale Investment Management Inc. | 0.2% | $6.1m |
| Dark Forest Capital Management LP | 0.07% | $744k |
| Entropy Technologies, LP | 0.03% | $723k |
| Weiss Asset Management LP | 0.01% | $782k |
| Mirabella Financial Services LLP | 0.01% | $142k |
| SummitTX Capital, L.P. | 0.01% | $392k |
| Caxton Associates LLP | 0.0% | $196k |
| Balyasny Asset Management L.P. | 0.0% | $1.8m |
| Capstone Investment Advisors, LLC | 0.0% | $281k |
| Farallon Capital Management, L.L.C. | 0.0% | $228k |
Ownership over time
Who discovered BCRX first? Beta
The run: Q1 2013 → Q2 2015, ×13
| Sarissa Capital Management LP high conviction | Q4 2020 | – | +7.6 pts |
| RA Capital Management, L.P. high conviction | Q1 2012 | – | +3.8 pts |
| Great Point Partners LLC high conviction | Q1 2018 | – | +3.7 pts |
| DG Capital Management, LLC | Q2 2020 | – | +2.6 pts |
| Pura Vida Investments, LLC | Q4 2019 | – | +0.3 pts |
| Avoro Capital Advisors LLC | Q3 2016 | – | −0.2 pts |
| Oracle Investment Management Inc high conviction | Q1 2021 | – | −0.4 pts |
| DAFNA Capital Management LLC | Q2 2015 | – | −3.6 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.